Sign In
Buy VRNA
$106.91
+0 (+0%)
At Close: Jan 06, 2026
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of V
Merck's VRNA Buyout to Add Novel COPD Therapy: How to Play the Stock?
09:20am, Friday, 11'th Jul 2025
MRK's $10B buyout of VRNA brings in Ohtuvayre, a unique COPD therapy set to bolster its cardio-pulmonary portfolio.
Major deals involving U.S. drugmakers and biotechs over the past decade
01:46pm, Wednesday, 09'th Jul 2025
Merck is acquiring UK-based Verona Pharma for about $10 billion, as part of the U.S. drugmaker's strategy to diversify beyond its blockbuster cancer treatment Keytruda.
Merck to Buy Verona Pharma for Around $10 Billion
12:36pm, Wednesday, 09'th Jul 2025
Merck agreed to buy respiratory drugmaker Verona Pharma for about $10 billion as it tries to make up for huge expected patent losses. Sales could fall by $18 billion over the next five years.
VRNA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Verona Pharma plc Is Fair to Shareholders
12:07pm, Wednesday, 09'th Jul 2025
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Verona Pharma plc (NASDAQ: VRNA) to Merck for $107.00 per American Depository Share is fa
Verona Pharma Stock Jumps 20% on $10B Buyout Offer From Merck
10:20am, Wednesday, 09'th Jul 2025
VRNA jumps 20% after Merck unveils buyout to add COPD drug Ohtuvayre and reduce its reliance on Keytruda.
Merck Strikes $10-Billion Deal For Verona, Secures First-In-Class COPD Drug
09:03am, Wednesday, 09'th Jul 2025
Merck & Co. Inc. MRK agreed on Wednesday to acquire Verona Pharma plc VRNA for $107 per American Depository Share (ADS) for a total transaction value of approximately $10 billion. Each ADS represents
Merck Plots $10 Billion Takeover Of COPD Drugmaker Verona Pharma
09:00am, Wednesday, 09'th Jul 2025
Merck said Wednesday it would buy COPD drugmaker Verona Pharma for $10 billion. The news sent Verona stock flying.
Verona Pharma shares jump with Merck set to acquire company in $10 billion deal
08:13am, Wednesday, 09'th Jul 2025
Merck announced Wednesday it will acquire UK-based Verona Pharma for approximately $10 billion, deepening its commitment to respiratory treatments as the company prepares for a revenue gap following t
Merck dives into COPD treatments with $10 billion purchase of Verona Pharma
07:48am, Wednesday, 09'th Jul 2025
Verona Pharma's stock soars toward a record after $10 billion buyout deal with Merck.
Verona Pharma Stock Jumps 21%. It's Being Bought for $10 Billion by Merck.
07:14am, Wednesday, 09'th Jul 2025
The deal is expected to close in the fourth quarter of 2025.
Merck to Buy Verona Pharma in $10 Billion Deal
06:48am, Wednesday, 09'th Jul 2025
Merck has struck a roughly $10 billion deal to buy Verona Pharma, bolstering its lineup as it braces for the 2028 loss of patent exclusivity for the blockbuster cancer drug Keytruda.
Merck to acquire Verona Pharma for $10 billion
06:39am, Wednesday, 09'th Jul 2025
Merck will buy UK-based Verona Pharma for about $10 billion, the companies said on Wednesday, strengthening the U.S. firm's presence in respiratory treatments as it readies for the patent expiry of it
RAHWAY, N.J. & RALEIGH, N.C.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a biopharmaceutical
Meck looks to soften impact of Keytruda cliff with $10bn tilt for Verona Pharma
04:01am, Wednesday, 09'th Jul 2025
Facing a looming patent cliff on its blockbuster cancer drug Keytruda, Merck & Co Inc (NYSE:MRK, ETR:6MK) is putting the finishing touches to a $10 billion deal to acquire Verona Pharma, a specialist
